Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.
Follow ADAPY
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '24 | Dec '24 | Mar '25 | Jun '25 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
186.09 | 151.61 | 59.56 | 26.06 |
Receivables |
12.50 | 14.38 | 4.38 | 9.31 | |
Inventory |
1.87 | 7.32 | 11.76 | 11.41 | |
Other current assets |
43.75 | 13.73 | 27.29 | 31.33 | |
Total current assets |
244.21 | 187.04 | 103.00 | 78.12 | |
Property, Plant, Equpment (Net) |
44.80 | 31.31 | 29.72 | 28.15 | |
Goodwill and Intangible Assets (Total) |
4.28 | 8.52 | 3.81 | 3.81 | |
Long-term assets (Other) |
3.65 | 2.07 | 2.33 | 1.81 | |
Total non-current assets |
73.22 | 59.38 | 55.07 | 52.52 | |
Total Assets |
317.44 | 246.42 | 158.07 | 130.63 | |
Accounts Payable |
9.07 | 40.98 | 5.70 | 9.42 | |
Accrued Expenses |
31.50 | 32.92 | 24.86 | 24.53 | |
Current Revenue (Deferred) |
18.71 | 12.30 | 12.44 | 10.70 | |
Other current liabilities |
— | 6.85 | 3.44 | 2.36 | |
Total current liabilities |
63.46 | 64.85 | 51.07 | 51.51 | |
Long Term Debt (Total) |
49.87 | 50.24 | 25.41 | 25.68 | |
Non-current Revenue (Deferred) |
98.73 | 95.82 | 95.98 | 101.42 | |
Non-current Liabilities (Other) |
4.94 | 3.15 | 4.37 | 4.49 | |
Total non-current liabilities |
173.99 | 168.53 | 144.43 | 150.08 | |
Total liabilities |
237.45 | 233.38 | 195.50 | 201.59 | |
Additional Paid In Capital |
1,102.81 | 828.22 | 1,106.46 | 1,109.41 | |
Common Stock (Net) |
2.08 | 2.09 | 2.10 | 2.16 | |
Retained Earnings |
(1,019.77) | (938.50) | (1,141.57) | (1,171.91) | |
Shareholders Equity (Other) |
— | 131.01 | — | — | |
Common Equity (Total) |
79.99 | 13.04 | (37.43) | (70.96) | |
Shareholders Equity (Total) |
79.99 | 13.04 | (37.43) | (70.96) | |
Shareholders Equity and Liabilities (Total) |
317.44 | 246.42 | 158.07 | 130.63 | |
Shares (Common) |
255.82 | 255.94 | 257.85 | 265.05 | |
Shareholders Equity (Tangible) |
75.71 | 4.52 | (41.23) | (74.76) | |
Net Debt |
(136.22) | (101.37) | (34.15) | (0.39) | |
Total Debt |
49.87 | 50.24 | 25.41 | 25.68 |